Michael Spedding

Q: What Schools Are Affiliated With Michael Spedding

Michael Spedding is affiliated with the following schools: University of California, Berkeley, California Institute of Technology, University of Sunderland, University of Chicago, Stanford University

Michael Spedding's AcademicInfluence.com Rankings

Michael Spedding

Computer Science

#7044

World Rank

#7419

Historical Rank

Computational Linguistics

#1335

World Rank

#1350

Historical Rank

Machine Learning

#2478

World Rank

#2510

Historical Rank

Artificial Intelligence

#2764

World Rank

#2807

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Michael Spedding's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Michael Spedding Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael Spedding's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels (2003) (7161)
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY (2017) (1500)
A Unified Nomenclature System for the Nuclear Receptor Superfamily (1999) (1152)
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands (2015) (1100)
Functional Selectivity and Classical Concepts of Quantitative Pharmacology (2007) (1078)
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy (2012) (934)
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands (2013) (906)
Overview of Nomenclature of Nuclear Receptors (2006) (642)
The Concise Guide to Pharmacology 2013/14: G Protein-Coupled Receptors (2013) (586)
A nomenclature for ligand-gated ion channels (2009) (562)
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology (2003) (546)
International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List (2005) (491)
The Concise Guide to Pharmacology 2013/14: Enzymes (2013) (443)
Altering the course of schizophrenia: progress and perspectives (2016) (390)
The hippocampal–prefrontal pathway: The weak link in psychiatric disorders? (2013) (345)
Classification of calcium channels and the sites of action of drugs modifying channel function. (1992) (314)
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing (2018) (300)
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers (2007) (299)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets (2019) (295)
Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. (2004) (294)
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview (2017) (266)
International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands (2013) (261)
The Concise Guide to PHARMACOLOGY 2015/16: Overview (2015) (256)
The Concise Guide to Pharmacology 2013/14: Ion Channels (2013) (249)
A functional correlate for the dihydropyridine binding site in rat brain (1985) (245)
Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: Reversal by tianeptine (2004) (226)
International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function (2005) (225)
IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels (2008) (220)
How can drug discovery for psychiatric disorders be improved? (2007) (219)
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. (1994) (209)
International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands (2014) (183)
The Concise Guide to Pharmacology 2013/14: Catalytic Receptors (2013) (151)
The IUPHAR/BPS Guide to PHARMACOLOGY database (GtoPdb) in 2018: new features and updates (2018) (150)
The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY (2019) (147)
The Concise Guide to Pharmacology 2013/14: Overview (2013) (143)
Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine (2007) (134)
Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: Importance for psychiatric diseases (2009) (132)
The Concise Guide to Pharmacology 2013/14: Transporters (2013) (129)
BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II (2004) (126)
The Concise Guide to Pharmacology 2013/14: Ligand-Gated Ion Channels (2013) (126)
Calcium antagonist subgroups (1985) (124)
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. (1995) (122)
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature (2015) (122)
α2‐Adrenoceptor subtypes and imidazoline‐like binding sites in the rat brain (1990) (117)
IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data (2010) (111)
IUPHAR-DB: updated database content and new features (2012) (104)
Mitochondria as target for antiischemic drugs. (2001) (100)
The Concise Guide to Pharmacology 2013/14: Nuclear Hormone Receptors (2013) (98)
Sub-Anesthetic Ketamine Modulates Intrinsic BOLD Connectivity Within the Hippocampal-Prefrontal Circuit in the Rat (2014) (97)
Alpha 2-adrenoceptors: more subtypes but fewer functional differences. (1994) (96)
The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study (2003) (93)
Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation (2009) (93)
Brain‐derived neurotrophic factor‐mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathways (2012) (90)
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. (1998) (90)
Inhibition of the constitutive activity of human 5‐HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635 (1997) (85)
Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats (2015) (81)
X. International Union of Pharmacology recommendations for nomenclature of new receptor subtypes. (1996) (81)
A proposal for an updated neuropsychopharmacological nomenclature (2014) (80)
Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission (1999) (80)
Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: How important is BDNF? (2014) (79)
Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase (2015) (77)
Direct inhibitory effects of some ‘calcium‐antagonists’ and trifluoperazine on the contractile proteins in smooth muscle (1983) (76)
(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists. (2008) (76)
"Calcium antagonists": a class of drugs with a bright future. Part II. Determination of basic pharmacological properties. (1984) (75)
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. (1997) (75)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets (2021) (75)
Protective effects of ranolazine in guinea‐pig hearts during low‐flow ischaemia and their association with increases in active pyruvate dehydrogenase (1993) (74)
Direct activation of Ca2+ channels by palmitoyl carnitine, a putative endogenous ligand (1987) (73)
Olympics: Run for your life (2012) (73)
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. (1998) (73)
Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain (2003) (72)
Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration (2011) (70)
A pathophysiological paradigm for the therapy of psychiatric disease (2005) (69)
Endocannabinoids potently protect the newborn brain against AMPA‐kainate receptor‐mediated excitotoxic damage (2006) (67)
Neurotrophins and cytokines in neuronal plasticity. (2008) (66)
ANTAGONISM OF ADENOSINE 5′‐TRIPHOSPHATE‐INDUCED RELAXATION BY 2‐2′‐PYRIDYLISATOGEN IN THE TAENIA OF GUINEA‐PIG CAECUM (1975) (65)
Activators and inactivators of Ca++ channels: new perspectives. (1985) (63)
Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule (2012) (62)
Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2. (1995) (61)
The influence of the initial stretch and the agonist‐induced tone on the effect of basal and stimulated release of EDRF (1990) (60)
A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development: IUPHAR Review 29 (2020) (59)
Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA‐, α1‐ and 5‐HT2A‐receptors (2002) (58)
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. (2008) (58)
Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors. (1994) (57)
Protection of stress-induced impairment of hippocampal/prefrontal LTP through blockade of glucocorticoid receptors Implication of MEK signaling (2008) (56)
GAP-43 is essential for the neurotrophic effects of BDNF and positive AMPA receptor modulator S18986 (2009) (56)
"Calcium antagonists": a class of drugs with a bright future. Part I. Cellular calcium homeostasis and calcium as a coupling messenger. (1983) (55)
Calcium Channel Activation Does Not Increase Release of Endothelial‐Derived Relaxant Factors (EDRF) in Rat Aorta Although Tonic Release of EDRF May Modulate Calcium Channel Activity in Smooth Muscle (1986) (55)
S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. (1994) (54)
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors: design, synthesis, pharmacology, (1998) (53)
IDENTIFICATION OF SEPARATE RECEPTORS FOR ADENOSINE AND ADENOSINE 5′‐TRIPHOSPHATE IN CAUSING RELAXATIONS OF THE ISOLATED TAENIA OF THE GUINEA‐PIG CAECUM (1976) (52)
Anti-Correlated Cortical Networks of Intrinsic Connectivity in the Rat Brain (2013) (52)
Brain plasticity and pathology in psychiatric disease: sites of action for potential therapy. (2003) (51)
Neuroprotective effects of modulators of P2 receptors in primary culture of CNS neurones (1999) (50)
Modulation of α1-Adrenoceptors in Rat Left Ventricle by Ischaemia and Acyl Carnitines: Protection by Ranolazine (1993) (48)
IUPHAR/BPS guide to pharmacology (2020) (47)
[3H]p-aminoclonidine and [3H]idazoxan label different populations of imidazoline sites on rat kidney. (1993) (46)
A one-step synthesis of 2-(2-Pyridyl)-3H-indol-3-one N-oxide: is it an efficient spin trap for hydroxyl radical? (2000) (45)
Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis (2018) (45)
The pharmacology of RS‐15385‐197, a potent and selective α2‐adrenoceptor antagonist (1993) (44)
RS‐45041‐190: a selective, high‐affinity ligand for I2 imidazoline receptors (1995) (42)
1,9-Alkano-bridged 2,3,4,5-tetrahydro-1H-3-benzazepines with affinity for the alpha 2-adrenoceptor and the 5-HT1A receptor. (1990) (40)
Neuroprotective properties of tianeptine: interactions with cytokines (2003) (40)
Are We Reaching the Limits of Homo sapiens? (2017) (40)
The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials (2021) (39)
Central effects of Ca2+ antagonists (1985) (38)
Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5-HT₇ receptor antagonist activity. (2011) (38)
Heterogeneity of α2‐adrenoceptors in rat cortex but not human platelets can be defined by 8‐OH‐DPAT, RU 24969 and methysergide (1990) (37)
The effects of AMPA receptor antagonists in models of stroke and neurodegeneration. (2005) (37)
The low-frequency blood oxygenation level-dependent functional connectivity signature of the hippocampal–prefrontal network in the rat brain (2013) (37)
Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS (2016) (36)
2,3-Benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects (2008) (36)
Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: antagonism of the effects of clozapine by modafinil (1999) (36)
Modulation of sexual behaviour in the rat by a potent and selective α2‐adrenoceptor antagonist, delequamine (RS‐15385‐197) (1996) (35)
Common efficacy of psychotropic drugs in restoring stress-induced impairment of prefrontal plasticity (2006) (34)
Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis (2017) (34)
Changing surface charge with salicylate differentiates between subgroups of calcium‐antagonists (1984) (32)
Antagonism of Ca2+-induced contractions of K+-depolarized smooth muscle by local anaesthetics. (1985) (32)
Selective inhibition of extra-synaptic α5-GABAA receptors by S44819, a new therapeutic agent (2017) (32)
New drug binding sites in Ca2+ channels. (1995) (31)
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture (2009) (31)
Differential effects of non-peptidic tachykinin receptor antagonists on Ca2+ channels. (1994) (31)
[3H]‐idazoxan binds with high affinity to two sites on hamster adipocytes: an α2‐adrenoceptor and a non‐adrenoceptor site (1989) (30)
Tianeptine and its enantiomers: effects on spatial memory in rats with medial septum lesions (2001) (30)
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist. (1989) (30)
Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia (1995) (30)
Species-conserved reconfigurations of brain network topology induced by ketamine (2016) (29)
Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). (2012) (29)
The AMPA receptor positive allosteric modulator, S18986, is neuroprotective against neonatal excitotoxic and inflammatory brain damage through BDNF synthesis (2009) (29)
In search of the mechanisms of ketamine's antidepressant effects: How robust is the evidence behind the mTor activation hypothesis [version 1; referees: awaiting peer review] (2016) (28)
Interaction of phorbol esters with Ca2+ channels in smooth muscle (1987) (27)
EFFECTS OF METOCLOPRAMIDE AND ISOPRENALINE IN THE RAT VAS DEFERENS; INTERACTIONS WITH α‐ADRENOCEPTORS (1980) (27)
Tianeptine potentiates AMPA receptors by activating CaMKII and PKA via the p38, p42/44 MAPK and JNK pathways (2011) (27)
A Three Binding Site Hypothesis for the Interaction of Ligands with Monoamine G Protein‐coupled Receptors: Implications for Combinatorial Ligand Design (1999) (26)
Potentiation by 2,2′‐pyridylisatogen tosylate of ATP‐responses at a recombinant P2Y1 purinoceptor (1996) (26)
Quantitative analysis of the dihydropyridines, 3-(2-furoyl)-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)- 1,4-dihydropyridine and nifedipine, by high-performance liquid chromatography with electrochemical detection. (1986) (25)
The protective effect of tianeptine on Gp120‐induced apoptosis in astroglial cells: role of GS and NOS, and NF‐κB suppression (2011) (25)
The neuroprotective activity of 8-alkylamino-1,4-benzoxazine antioxidants. (2001) (25)
A novel GABA(A) alpha 5 receptor inhibitor with therapeutic potential. (2015) (24)
A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development (2020) (23)
The effect of chronic tianeptine administration on the brain mitochondria: direct links with an animal model of depression (2016) (23)
S 14506: novel receptor coupling at 5-HT1A receptors (2001) (23)
A new nomenclature for classifying psychotropic drugs. (2017) (23)
Mss4 gene is up-regulated in rat brain after chronic treatment with antidepressant and down-regulated when rats are anhedonic. (2002) (23)
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture (2009) (23)
Neural control of dieting (1996) (23)
The effect of lifarizine (RS‐87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil (1993) (23)
Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis (2019) (23)
ANTAGONISM OF THE INHIBITORY EFFECTS OF ADENOSINE 5′‐TRIPHOSPHATE ON THE ISOLATED TAENIA OF THE GUINEA‐PIG CAECUM: STRUCTURE‐ACTIVITY RELATIONSHIPS WITHIN A SERIES OF ISATOGEN DERIVATIVES (1978) (22)
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors. (1991) (22)
The effects of calcium antagonists on calcium overload contractures in embryonic chick myocytes induced by ouabain and veratrine (1989) (21)
Drugs in sport: a scientist–athlete's perspective: from ambition to neurochemistry (2008) (21)
Multiple exposures to familiar conspecific withdrawal is a novel robust stress paradigm in ewes (2012) (21)
The problems associated with the use of 2,2′‐pyridylisatogen tosylate in evaluating the allegedly purinergic innervation of peripheral organs (1978) (21)
SLC6 neurotransmitter transporter family (2013) (21)
Interaction of palmitoyl carnitine with calcium antagonists in myocytes (1989) (21)
The age-performance relationship in the general population and strategies to delay age related decline in performance (2019) (20)
Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation (2017) (20)
Depression of Sympathetic Nervous Function by DL‐α‐Monofluoromethyldopa, an Enzyme‐Activated, Irreversible Inhibitor of L‐Aromatic Amino Acid Decarboxylase (1980) (20)
Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. (2020) (20)
The expanding role of immunopharmacology: IUPHAR Review 16 (2015) (19)
Assessment of “Ca2+-antagonist” effects of drugs in K+-depolarized smooth muscle (1982) (19)
Calcium Antagonist Properties of Diclofurime Isomers. II. Molecular Aspects: Allosteric Interactions with Dihydropyridine Recognition Sites (1987) (19)
Vasodilation by medroxalol mediated by beta 2-adrenergic receptor stimulation. (1983) (19)
Differences Between the Effects of Calcium Antagonists in the Pithed Rat Preparation (1982) (19)
2-2'-Pyridylisatogen, a selective allosteric modulator of P2 receptors, is a spin trapping agent. (1998) (17)
Interactions between a “calcium channel agonist”, Bay K 8644, and calcium antagonists differentiate calcium antagonist subgroups in K+-depolarized smooth muscle (1984) (16)
Behavioural pharmacology of the α5-GABAA receptor antagonist S44819: Enhancement and remediation of cognitive performance in preclinical models (2017) (16)
Pharmacology of sodium and calcium channel modulation in neurons: implications for neuroprotection. (1995) (16)
New directions for drug discovery (2006) (16)
The presence of β‐adrenoceptors in the guinea‐pig seminal vesicle (1972) (16)
Modulation of central noradrenergic function by RS‐15385‐197 (1993) (16)
Functional interactions of calcium‐antagonists in K+‐depolarized smooth muscle (1983) (15)
Clinical trials in neonates: ethical issues. (2007) (15)
Competitive interactions between Bay K 8644 and nifedipine in K+ depolarized smooth muscle: a passive role for Ca2+? (1985) (15)
Egis-11150: A candidate antipsychotic compound with procognitive efficacy in rodents (2013) (15)
Factors modifying the tissue selectivity of calcium-antagonists. (1990) (15)
Rapid effects of melatonin on hormonal and behavioral stressful responses in ewes (2013) (15)
Key challenges for the creation and maintenance of specialist protein resources (2015) (15)
Receptor nomenclature (15)
Selective antagonism of calcium channel activators by fluspirilene (1990) (14)
Proceedings: 2-2' pyridylisatogen tosylate: an antagonist of the inhibitory effects of ATP on smooth muscle. (1974) (14)
The hippocampal to prefrontal cortex circuit in mice: a promising electrophysiological signature in models for psychiatric disorders (2016) (14)
Receptor classification and nomenclature: the revolution and the resolution. (1994) (13)
THE MECHANISM OF THE RELAXANT EFFECT OF 2‐2′‐PYRIDYLISATOGEN ON THE ISOLATED TAENIA OF THE GUINEA‐PIG CAECUM (1978) (13)
Developments in purine and pyridimidine receptor‐based therapeutics (1996) (13)
Sodium modulation of 3H‐agonist and 3H‐antagonist binding to α2‐adrenoceptor subtypes (1993) (13)
Cerebral ischaemia reduces the density of 5-HT2 binding sites in the frontal cortex of the gerbil (1988) (12)
Resolution of controversies in drug/receptor interactions by protein structure. Limitations and pharmacological solutions (2011) (12)
Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (12)
Cognition- and circuit-based dysfunction in a mouse model of 22q11.2 microdeletion syndrome: effects of stress (2020) (12)
Future Directions for the Discovery of Natural Product-Derived Immunomodulating Drugs. (2022) (12)
Antagonists and Activators at Calcium Channels (1988) (11)
Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat (1998) (11)
Mitochondrial pharmacology: energy, injury and beyond (2014) (11)
Age-Related Upper Limits in Physical Performances. (2018) (11)
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site. (1990) (11)
Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain. (1990) (11)
Antagonists and the purinergic nerve hypothesis: 2, 2'-pyridylisatogen tosylate (PIT), an allosteric modulator of P2Y receptors. A retrospective on a quarter century of progress. (2000) (10)
Classification of calcium channels and calcium antagonists: Progress report (1992) (9)
Role of spin trapping and P2Y receptor antagonism in the neuroprotective effects of 2,2'-pyridylisatogen tosylate and related compounds. (2002) (8)
Calcium Antagonist Properties of Diclofurime Isomers. I. Functional Aspects (1987) (8)
Creating a specialist protein resource network: a meeting report for the protein bioinformatics and community resources retreat (2015) (8)
Interactions of palmitoyl carnitine with the endothelium in rat aorta (1990) (8)
International Union of Pharmacology. XXXI. Recommendations for the Nomenclature of Multimeric G Protein-Coupled Receptors (2002) (8)
Effects of EGIS-7625, a Selective and Competitive 5-HT2B Receptor Antagonist (2003) (8)
Plan S: A threat to quality of science? (2019) (8)
The guinea‐pig ileum preparation as a model for 5‐HT1A receptors: anomalous effects with RS‐30199–193 (1991) (8)
Strategies for neuroprotection in the newborn (2004) (8)
Stereospecific blockade of α2‐adrenoceptors by (+)‐butaclamol: implications for the characterization of dopamine receptors (1982) (7)
Structure-Affinity Relationships of 12-Sulfonyl Derivatives of 5,8,8a, 9,10,11,12,12a,13,13a-Decahydro-6H-isoquino(2,1-g)(1,6)naphthyridines at α-Adrenoceptors. (1991) (7)
Voltage-dependent calcium channels: structures and drug-binding sites. (1992) (7)
Nomenclature of calcium channels and channel modulators: IUPHAR classification. (1993) (7)
[Synaptic plasticity and neuropathology: new approaches in drug discovery]. (2005) (7)
Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet (2020) (7)
Acute tianeptine treatment selectively modulates neuronal activation in the central nucleus of the amygdala and attenuates fear extinction (2015) (7)
Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases. (2020) (7)
Reasons why stroke trials underestimate the neuroprotective effects of drugs. (2002) (7)
Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database (2020) (7)
Transduction Is a Major Factor Influencing Receptor Characterization (1997) (6)
Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors (2005) (5)
[Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine]. (1999) (5)
Pertussis toxin-sensitive G-protein activation does not influence the response to Bay K 8644 in embryonic chick myocytes. (1990) (5)
MDL 72567, a Dihydropyridine Calcium‐Antagonist, That Causes Vasodilation and Direct Sinus Bradycardia (1987) (5)
The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology (2020) (5)
Effects of EGIS-7229 (S 21407), a Novel Class III Antiarrhythmic Drug, on Myocardial Refractoriness to Electrical Stimulation In Vivo and In Vitro (2001) (5)
1,9-Alkano-Bridged 2,3,4,5-Tetrahydro-1H-3-benzazepines with Affinity for the α2-Adrenoceptor and the 5-HT1A Receptor. (1990) (4)
Adenosine receptors in the heart: controversy about signal transmission (1985) (4)
Acute Stress Affects the Expression of Hippocampal Mu Oscillations in an Age-Dependent Manner (2017) (4)
Approved drug and clinical target curation in the IUPHAR/BPS Guide to PHARMACOLOGY (2014) (3)
Vasodilation by Medroxalol Mediated by β2-Adrenergic Receptor Stimulation (1983) (3)
Ionotropic glutamate receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (3)
The α2-adrenoceptor antagonist SK&F 104078 has high affinity for 5-HT1A and 5-HT2 receptors (1989) (3)
Changes in [3H]‐PK 11195 and [3H]‐8‐OH‐DPAT binding following forebrain ischaemia in the gerbil (1993) (3)
Actions of palmitoyl carnitine in embryonic chick myocytes (1990) (3)
Up and Down Regulation of Synaptic Strength at Hippocampal to Prefrontal Cortex Synapses (2004) (3)
Antagonists and activators at calcium channels. Effects in the gastrointestinal tract. (1988) (3)
General discussion II (2008) (3)
Class A Orphans in GtoPdb v.2021.3 (2021) (2)
IUPHAR guidelines for classification of new receptor-subtypes. (1995) (2)
Sodium modulation of 3H-agonist and 3H-antagonist binding to alpha 2-adrenoceptor subtypes. (1993) (2)
Introduction to the special issue on High Resolution Neuropharmacology (2011) (2)
Effects of acyl carnitines on cardiac muscle (1990) (2)
Role of Lipids and Lipid Metabolites in Myocardial Ischaemia (1992) (2)
GuideToPharmacology.org – an update (2012) (2)
2,2'-Pyridylisatogen, an ATP receptor antagonist, revisited. (1994) (2)
Brain circuits at risk in psychiatric diseases and pharmacological pathways. (2020) (2)
Neuroprotection in the newborn infant: interactions between stress, glutamate, glucocorticoids and development (2001) (2)
Differential effects of calcium channel antagonists on histamine and pentagastrin-stimulated gastric acid secretion in the rat (1985) (2)
Current status of drug receptor nomenclature: receptor closure? The role of NC-IUPHAR (2004) (2)
Acylation Differentiates Two Forms of Agonist Binding to Rat 5‐HT1A Receptors (1997) (1)
The Guide to PHARMACOLOGY portal: A one-stop pharmacology shop (2013) (1)
Creating a specialist protein resource network (2015) (1)
Phenotypical Screening on Neuronal Plasticity in Hippocampal-Prefrontal Cortex Connectivity Reveals an Antipsychotic with a Novel Profile (2022) (1)
Aging, VO2 max, entropy, and COVID-19 (2022) (1)
The hippocampal to prefrontal cortex circuit in mice: a promising electrophysiological signature in models for psychiatric disorders (2015) (1)
The effects of 2-2'-pyridylisatogen tosylate on the electrical activity of smooth muscle of the isolated taenia caeci of the guinea-pig [proceedings]. (1978) (1)
Comparison Between the Effects of MDL 72567 and Nifedipine on Various Cardiovascular Parameters in Conscious Sinoaortic‐Denervated Rats and Sham‐Operated Controls (1987) (1)
Scientists on the Spot: the Guide to Immunopharmacology as a new resource for the cardiovascular community (2019) (1)
Editorial (2009) (1)
Sub-anesthetic ketamine modulates intrinsic BOLD connectivity in the hippocampal-prefrontal system in the rat : dose-dependence and PK / PD relationships (2012) (1)
Figure 3 raw data (2016) (1)
Dihydro-oxazolobenzodiazepinona derivatives, processes for their preparation and pharmaceutical compositions containing these compounds (2012) (1)
Guide to Immunopharmacology: a database to boost immunology education, research and therapy (2020) (1)
Calling all pharmacologists with time to spare! We need you! Build the drug discovery knowledge base, GuidetoPharmacology.org (2012) (1)
A modified guinea-pig stomach preparation [proceedings]. (1977) (1)
Thepharmacology ofRS-15385-197, a potentandselective M2-adrenoceptor antagonist (1993) (0)
Spedding replies: Lifarizine is not selective for Na+ channels (1995) (0)
New benzo-thiadiazine derivative, its preparation process and the pharmaceutical compositions containing it. (1995) (0)
P.2.003 Sub-anaesthetic ketamine modulates intrinsic blood oxygen level-dependent (BOLD) connectivity between the hippocampus and the prefrontal cortex in the rat (2013) (0)
Profound lipid dysregulation in mutant TDP-43 mice is ameliorated by the glucocerebrosidase 2 inhibitor ambroxol (2022) (0)
S.03.01 Alterations of the hippocampal-prefrontal pathway in schizophrenia: effect of antipsychotic drugs (2013) (0)
The effect of chronic tianeptine administration on the brain mitochondria: direct links with an animal model of depression (2016) (0)
P.2.d.015 Glutamatergic deficits and differential antidepressant regulation in rat model of depression (2011) (0)
Class A Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (0)
Inhibition of peripheral sympathetic function by alpha-monofluoromethyldopa, an irreversible inhibitor of aromatic amino acid decarboxylase [proceedings]. (1979) (0)
A simple, inexpensive method of collection, storage and analysis of data for the BBC microcomputer (1987) (0)
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for .alpha.-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled .alpha.2-adrenoceptor vs. the [3H]yohimbime-labeled site [Erratum to document cited in CA112(7):55713w (1990) (0)
S.18.04 Animal models of neuropsychiatric disorders: ketamine and related drugs (2012) (0)
S.03.03 Brain connectivity modulation by novel antipsychotics: an electrophysiological approach (2010) (0)
Heterogeneity ofx2-adrenoceptors inratcortexbutnothuman platelets canbedefined by8-OH-DPAT, RU 24969and methysergide (1990) (0)
Explorer International Union of Basic and Clinical Pharmacology . LXXXVIII . G protein-coupled receptor list (2013) (0)
P.2.d.003 Excitatory effect of the atypical antidepressant tianeptine in the rat hippocampus: in vitro study (2008) (0)
Joint ICMAN and IUPHAR natural products section meeting. Aberdeen UK 27-29th September 2017. (2017) (0)
Effect of Chronic Treatment with Tianeptine in Combination with Corticosterone on Rat Brain Mitochondrial Function (2012) (0)
A novel benzolithiadicin compound, a process for its preparation and pharmaceutical compositions containing it (1995) (0)
New derivatives dihydro-oxazolobenzodiazepinones, their process for the preparation and pharmaceutical compositions containing them (2011) (0)
Receptor Nomenclature for Publications in Indian Journal of Pharmacology (2016) (0)
New naphthalenic derivatives, process for their preparation and pharmaceutical compositions containing them. (2007) (0)
Environmental pharmacology—Dosing the environment: IUPHAR review 36 (2022) (0)
The potential impact of COVID-19 on therapeutic research worldwide (2020) (0)
Acyl carnitines and myocardial ischaemia (1990) (0)
Modification of the effects of bay k 8644 1 4 dihydro 2 6 dimethyl 5 nitro 4 2 trifluoromethylphenyl 3 pyridinecarboxylic acid methyl ester in rat aorta by the endothelium (1985) (0)
Black and white and alternate process photography by Michael Spedding (2002) (0)
Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis (2017) (0)
The International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR): Relevance to pharmacology today and challenges for the future (2018) (0)
P2-009 The positive allosteric modulator of AMPA receptors, S 18986, is neuroprotective in neonatal mouse brain: interaction with neurotrophins (2004) (0)
(3aS) -5,5-dioxo-2,3,3a, 4-tetrahydro-1H-pyrrolo [2,1-c] [1,2,4] benzothiadiazine S-enantiomer form, method for its preparation and pharmaceutical compositions containing compositions (1995) (0)
Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats (2015) (0)
Measurement and analysis of analogue signals from a Linseis chart recorder using a BBC microcomputer (1987) (0)
Benzothiadiazinderivat, process for their preparation and to pharmaceutical compositions containing the derivative (1995) (0)
Alliance between the International Union of Basic and Clinical Pharmacology and the Indian Pharmacological Society for Health, Education, Drug Discovery, and Development in India (2016) (0)
The role of lipid metabolites in calcium mobilisation during ischaemia: potential new therapies (1990) (0)
New Naphtalinderivate, their preparation process and the pharmaceutical compositions containing them (2007) (0)
New benzothiadiazine compound, its production, and medicinal composition containing the same (1995) (0)
Effect of chronic stress and antidepressant treatment on rat brain mitochondrial reactive oxygen species (ROS) production. (2010) (0)
Poster #77 CHARACTERISATION OF THE NOVEL PROCOGNITIVE ANTIPSYCHOTIC EGIS 11150 IN THE HIPPOCAMPUS AND NEOCORTEX/N VITRO. (2012) (0)
New derivative of benzothiadiazine his Depreparation process and the pharmaceutical compositions containing the (1994) (0)
New N-benzylpiperazinforbindelser, process for their preparation and pharmaceutical compositions containing them (2002) (0)
New derivatives of N-benzylpiperazine, their process for the preparation and pharmaceutical compositions containing them (2001) (0)
Corrigendum to "Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review" [Pharmacol. Res. 177 (2022) 106076]. (2022) (0)
P.1.d.019 Circadian pattern of wheel running activity of four laboratory mouse strains (2010) (0)
Benzothiadiazine derivatives, to processes for their preparation and pharmaceuticals containing Zuzammensetzungen (1995) (0)
Receptor Nomenclature for Publications in Indian Journal of Pharmacology (2016) (0)
Paired vasa deferentia: a method of reducing variability in the response to drugs. (1974) (0)
Theinfluence oftheinitial stretch andtheagonist-induced tone on theeffect ofbasal andstimulated release ofEDRF (1990) (0)
Neuroprotection in the newborn infant (2001) (0)
New Directions in Cerebral Ischemia: Sodium and Calcium Channel Modulators (1995) (0)
I9 IUPHAR: Immunology, metabolism and natural products (2017) (0)
Quantification of experimentally induced ischaemic damage to smooth muscle cell membranes within the wall of resistance arteries (1991) (0)
The alpha 2-adrenoceptor antagonist SK&F 104078 has high affinity for 5-HT1A and 5-HT2 receptors. (1989) (0)
Specific modulation of P2 purinoceptors by 2,2'-pyridilisatogen (PIT). (1996) (0)
Channel nomenclature: IUPHAR recommendations. (1993) (0)
Use of agomelatine for the preparation of medicaments for the treatment of periventricular leukomalacia (2007) (0)
Present and future IUPHAR plans for network support in training and capacity building in pharmacology and clinical pharmacology in resource strained countries (2018) (0)
Using tianeptine for obtaining medicaments intended for treating pathologies of neurodegeneration (1999) (0)
[ 3 H ]-YOHIMBINE AND [ 3 H ]-IDAZOXAN BINDING TO RAT BRAIN (2006) (0)
Benzothiadiazine derivatives, to processes for their preparation and pharmaceutical compositions containing them (1995) (0)
3- (2- (furoyl) -5- (optionally substituted) alkoxy-carbonyl-2,6-dimethyl-4- (2-nitrophenyl) -1,4-dihydropyridines and pharmaceutical preparation containing such compounds (1984) (0)
The IUPHAR Database: Tools to navigate pharmacological space (2010) (0)
P.1.g.008 Sub-anesthetic ketamine modulates intrinsic BOLD connectivity between the hippocampus and the prefrontal cortex in the rat (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael Spedding?

Michael Spedding is affiliated with the following schools:

Michael Spedding's Academic­Influence.com Rankings

Michael Spedding's Degrees

Similar Degrees You Can Earn

Why Is Michael Spedding Influential?

Michael Spedding's Published Works

Published Works

What Schools Are Affiliated With Michael Spedding?

Michael Spedding's AcademicInfluence.com Rankings